Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
News Jun 19, 2014
Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of € 1.0 m to Evotec.
The milestone was for the transition of a back-up compound from a respiratory programme into pre-clinical development.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We have now achieved twenty three milestones as part of the collaboration with Boehringer Ingelheim. The completed research phase of this alliance has led to significant potential clinical milestones and royalties for compounds that are already in pre-clinical and clinical development if they progress successfully.”
Synthetic biologists look to re-engineer cells to make complex molecules for specific needs, including pharmaceuticals. But the trial-and-error process is difficult and time-consuming. Now, by combining two state-of-the-art research approaches, researchers have created a fast, efficient way to engineer and analyze metabolic pathways.READ MORE